SEC Tracker
Get the app

aTYR PHARMA ATYR

aTyr Pharma announces reverse stock split

Item 5.03 Amends charter or bylaws

Form
8-K
Filed
Importance
Routine
  1. 1-for-40 reverse stock split effective Oct 28, 2026
  2. Shares outstanding to drop from 100.5M to 2.5M
  3. Stock options and warrants adjusted proportionally
  4. Trading to resume on Nasdaq under same ticker

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when aTYR PHARMA files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Arvinas ARVN public float $469M, Jun 30, 2025
  2. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025
  3. Zevra Therapeutics ZVRA public float $455M, Jun 30, 2025
  4. Theravance Biopharma TBPH public float $449M, Jun 30, 2025
  5. Myriad Genetics MYGN public float $494M, Jun 30, 2025